Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126018
Filing Date
2024-11-13
Accepted
2024-11-13 10:30:25
Documents
87
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-20240930.htm   iXBRL 10-Q 2720727
2 EX-10.6 mcrb-ex10_6.htm EX-10.6 45458
3 EX-10.7 mcrb-ex10_7.htm EX-10.7 44940
4 EX-31.1 mcrb-ex31_1.htm EX-31.1 13124
5 EX-31.2 mcrb-ex31_2.htm EX-31.2 12991
6 EX-32.1 mcrb-ex32_1.htm EX-32.1 7998
7 EX-32.2 mcrb-ex32_2.htm EX-32.2 8049
  Complete submission text file 0000950170-24-126018.txt   11313082

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20240930.xsd EX-101.SCH 1992699
90 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20240930_htm.xml XML 1675311
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 241451834
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)